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ABSTRACT 
 
Sanchis-Gomar F, Martinez-Bello VE, Derbré F, García-López E, García-Valles R, Brioche T, Ferrando B, 
Ibañez-Sania S, Pareja-Galeano H, Gomez-Cabrera MC, Viña J. Rapid hemodilution induced by 
desmopressin after erythropoietin administration in humans. J. Hum. Sport Exerc. Vol. 6, No. 2, pp. 315-
322, 2011. We have shown that treatment with desmopressin has a very effective hemodilution effect in 
healthy humans. These results led us to suggest the possible role of desmopressin to mask blood doping in 
sports. Based on our results, the World Anti-Doping Agency included the desmopressin in the 2011 List of 
Prohibited Substances and Methods. On this occasion, the aim of our study was to test the desmopressin-
induced hemodilution after rHuEpo administration in humans. This was an intra-subject, crossover study in 
which five physically active males acted as their own controls. A basal blood sample was taken on their first 
visit to the laboratory. The next day, the subjects began the treatment. They received a subcutaneous 
rHuEpo injection three times/week for a two-week period. On the second visit to the laboratory, seventeen 
days later, a blood sample was taken. Thereafter, the subjects received an oral dose of 4.3 µg/kg of 
desmopressin and were instructed to ingest 1.5 liters of mineral water during the following fifteen minutes. 
Three hours after the water ingestion a second blood sample was obtained. The samples were analyzed for 
hematocrit (HCT), hemoglobin (Hb), reticulocytes (Ret%) and OFF Hr-Score. We found significantly higher 
HCT, Hb and Ret% levels after rHuEpo administration. Administration of desmopressin significantly 
decreased the HCT and Hb values but we did not find significant changes in Ret%. The values of the OFF 
Hr-Score also decreased after treatment with desmopressin. Desmopressin has a very effective 
hemodilution effect after rHuEpo administration and significantly modifies the hematological values 
measured by the anti-doping authorities to detect blood doping. We consider that these results reinforce the 
conclusions reported in our first study and confirm that desmopressin is a very effective masking agent for 
blood doping. Key words: HEMOGLOBIN, HEMATOCRIT, RETICULOCYTES, STIMULATION INDEX 
AND PLASMA VOLUME EXPANDERS 
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INTRODUCTION 
 
The World Anti-Doping Agency (WADA) implemented the Athlete Blood Passport (ABP) to detect athletes 
using performance-enhancing drugs such as rHuEpo (Ashenden et al., 2011). This strategy relies on 
detecting abnormal variations in hematological variables over time to facilitate indirect detection of doping 
on a longitudinal basis, rather than on the traditional direct detection of doping (Gilbert, 2010).  The major 
physiological effect of the treatment with erythropoiesis stimulating agents, such as rHuEpo, is the increase 
in hematocrit/hemoglobin values and improvements in aerobic sport performance (Brien & Simon, 1987; 
Ekblom et al., 1976). Thus, athletes have adopted new strategies to manipulate their blood to adjust their 
values between the physiological limits (Thevis et al., 2000). 
 
The prohibited list of substances in sports (WADA, 2011)  includes a group of masking agents. Masking 
agents are drugs or compounds that are taken with the express purpose of hiding the presence of specific 
illegal drugs that are screened for athletic drug testing. Masking agents are prohibited at all times, in and out 
of competition, and they include diuretics, plasma volume expanders (PVEs) and probenecid (Ventura & 
Segura, 2010). When an athlete presents hematological values higher than those allowed, a fast way to 
decrease them is to use PVEs such as albumin, dextran, and/or hydroxyethyl starch (Guddat et al., 2005; 
Guddat et al., 2008). 
 
Desmopressin, 1-desamino-8-D-arginine-vasopressin, is a synthetic analogue of vasopressin with 
increased antidiuretic activity and decreased pressor activity (Robinson, 1976). It works by limiting the 
amount of water that is eliminated in urine and  binds to V2 receptors in renal collecting ducts, increasing 
water reabsorption (Levy, 2008). Desmopressin is used to prevent or control polyuria, polydipsia, and 
dehydration in patients with central diabetes insipidus (Kim et al., 2004) and in primary nocturnal enuresis 
(Dimson, 1977).  
 
Our group recently characterized desmopressin-induced hemodilution in humans and its possible 
implications in blood doping (Sanchis-Gomar et al., 2010b). Based on our results, the World Anti-Doping 
Agency included desmopressin in the 2011 List of Prohibited Substances and Methods (WADA, 2011). 
 
The main limitation of our first study was that we recruited subjects with physiological blood levels, i.e. 
subjects who were not previously treated with erythropoiesis stimulating agents such as rHuEpo, 
darbepoietin, CERA etc. The aim of the present study is to determine the effects of rHuEpo administration 
and the modifications achieved after desmopressin treatment on hematocrit and hemoglobin values, 
reticulocytes and the OFF-Hr Score. 
 
MATERIAL AND METHODS 
 
Five physically active male subjects volunteered for this study. All were non-smokers and free of any known 
illnesses as ascertained by a questionnaire.  
 
This was an intra-subject, crossover study in which the subjects acted as their own controls. All the 
subjects were required to visit the laboratory on two occasions with an interval of seventeen days. All the 
subjects were instructed to follow the same dietary and training pattern the week before the analysis. 
Subjects were instructed to avoid any strenuous exercise for four days prior to the analysis. On their first 
visit to the laboratory, the subjects were seated for 30 minutes and a basal blood sample was taken in this 
position. The next day we began the rHuEpo treatments (Figure 1). 
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Figure 1. Design of the study. On their first visit to the laboratory a basal blood sample was taken. The next 
day, subjects began the treatment. The received subcutaneous rHuEpo injections 3 times/week for a 2-
week period. On the second visit to the laboratory, seventeen days after, a blood sample was taken. 
Thereafter, they received an oral dose of 4.3 µg/kg of desmopressin and were instructed to ingest 1.5 liters 
of mineral water during the following fifteen minutes. Three hours after the water ingestion, a second blood 
sample was obtained. 
 
Recombinant human erythropoietin treatment 
The subjects received rHuEpo (Epoetin alpha; Eprex; Janssen-Cilag) injections at a dose of 70 IU/kg for a 
two-week period (three injections/week); the injections were given subcutaneously (see Figure 1). 
 
The subjects were supplemented daily with iron tablets one week before the study commenced until one 
week after it terminated (Fero-gradumet; ~105 mg of elemental iron derived from 350 mg of dried ferrous 
sulphate). 
 
Desmopressin treatment 
On day seventeen, all the subjects visited the laboratory at 9 a.m. On arrival the subjects remained seated 
for 30 minutes and a basal blood sample was taken in this position. Immediately after the sample was 
taken, the subjects received an oral dose of 4.3 µg/kg of desmopressin and they were instructed to ingest 
1.5 liters of mineral water (sodium content, 13.2 mg/L) during the following 15 minutes. Three hours after 
the water ingestion a second blood sample was obtained.   
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Therefore, three blood samples (Figure 1) were collected on days 0 and seventeen (on two occasions). All 
of them were collected at the same time and under the same conditions (temperature and humidity) from a 
superficial vein in the antecubital fossa while the subjects were seated. The blood samples were divided 
into three tubes: BD Vacutainer blood collection tubes containing EDTA. 
 
All subjects were informed verbally and in writing about the nature of the study, including all potential risks. 
The Committee on Ethics in Research of the Faculty of Medicine, University of Valencia, granted ethical 
approval. 
 
Determinations 
Whole Blood analysis: Hematocrit, hemoglobin, and reticulocytes were analyzed within three hours of blood 
collection using a SYSMEX XT2000i hematology analyzer (Roche Diagnostics). The direct measurements 
performed by the SYSMEX XT2000i on erythrocytes included: count, size, and total hemoglobin. Direct 
reticulocyte measurements included the percentage of reticulocytes (R%). The stimulation index was 
calculated from hemoglobin (Hb in g/L) and reticulocytes (R in %), on the OFF-model score: Hb - 60√R. 
 
Statistical analysis   
For the statistical analysis of the results, the mean was taken as the measurement of the main tendency 
while the standard deviation was taken as the dispersion measurement. According to normality, continuous 
data were analyzed with the two-tailed paired samples t- test. The alpha level for statistical significance was 
set at p<0.05. We used SPSS software (version 17.0; SPSS Inc, Chicago, IL) for all the statistical analyses. 
 
RESULTS  
 
Effect of the administration of 4.3 µg/kg of desmopressin on hemoglobin, hematocrit, reticulocytes and 
on OFF-Hr Score, after rHuEpo administration. 
 
In Figure 2 we show significantly higher Hb, HCT and Ret% levels after rHuEpo administration 
demonstrating that rHuEpo injections were effective in our study. The Hb values (g/dL) increased from 
15.2 ± 0.6 before rHuEpo administration to 16.6 ± 0.5 (p < 0.01) after treatment. The HCT (%) 
increased from 45.7 ± 1.3 before rHuEpo administration to 49.4 ± 0.7 (p < 0.01) after treatment. The 
percentage of reticulocytes increased from 0.7 ± 0.1 before rHuEpo administration to 1.5 ± 0.4 (p < 
0.01) after treatment. Finally, the OFF-Hr Score decreased from 101.7 ± 6.8, before rHuEpo 
administration, to 92.9 ± 10.6.  
 
A statistically significant decrease in Hb and HCT concentration was observed three hours after 
treatment with desmopressin in all the subjects (Figure 2). The Hb concentration decreased from 16.6 ± 
0.5 before the treatment to 15.5 ± 0.5 (p < 0.01) post treatment. The HCT percentage decreased from 
49.4 ± 0.7 before the treatment to 46.6 ± 1.4 (p < 0.01) after the treatment. Although a decrease in 
Ret% was also found after treatment with desmopressin, this modification was not statistically significant 
(1.5 ± 0.4 to 1.3 ± 0.5). However, the OFF-Hr Score value, calculated using the Ret%, decreased 
significantly after  treatment with desmopressin, from 101.7± 6.8 to 86.5 ± 10.4 (p < 0.05). 
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Figure 2. Hemoglobin, hematocrit, reticulocytes concentration and OFF-Hr Score values after rHuEpo 
administration and after treatment with desmopressin. Data presented as mean (±SD). Hematological 
values were measured in basal and after treatment conditions. (*) indicates significant difference (p < 
0.05, two-tailed paired samples t –test between two groups). (**) indicates significant difference (p < 
0.01, two-tailed paired samples t –test between two groups). 
 
 
DISCUSSION AND CONCLUSIONS 
 
Increasing the blood content by raising hemoglobin/hematocrit values is an easy method to improve oxygen 
delivery and improve sport performance (Ekblom et al., 1976). Illegal methods for raising hematocrit values 
include blood doping (infusion of packed autologous, homologous, heterologous, red blood cells) and 
administration of erythropoiesis stimulating agents such as rHuEpo, darbepoietin, CERA, etc. (Cooper & 
Beneke, 2008). In view of the long list of agents and techniques in blood doping practices, it is necessary to 
have a wide range of tests to detect them. The indirect method to detect blood doping is based on the 
determination of several blood parameters: Hb, HCT, Ret% and in the calculation of the stimulation index 
(OFF-Hr Score). This index consists of applying a statistical model using two blood parameters: percentage 
of reticulocytes and hemoglobin (Hb in g/L) on the OFF-model score: Hb - 60√R. Both parameters are 
substantially altered after a period of EPO administration (Gore et al., 2003; Parisotto et al., 2003; Parisotto 
et al., 2001; Sharpe et al., 2006). The reticulocytes are a crucial parameter in the ABP. Their values 
increase significantly after rHuEpo injection (Audran et al., 1999; Parisotto et al., 2001) or phlebotomy 
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(Damsgaard et al., 2006; Morkeberg et al., 2009a), and decrease when rHuEpo treatment ceases (Gore et 
al., 2003) or blood is re-infused (Morkeberg et al., 2009b). The accuracy of this method for the indirect 
detection of EPO abuse has been very well documented (Gore et al., 2003; Parisotto et al., 2001; Sharpe 
et al., 2006). This is why the OFF-Hr Score has been adopted by the anti-doping agencies (Gore et al., 
2003). 
 
It has been demonstrated that the combination of PVEs and rHuEpo can be advantageous for the cheaters. 
PVEs are banned because raising plasma volume can potentially be performance enhancing (preventing 
dehydration) (Guddat et al., 2008) and its use can mask a rise in hematological values caused by illegal 
methods. For instance, the members of the Finnish skiing team used hydroxyethyl starch to mask blood 
doping, prior to the world Nordic ski championship in 2001 (Cooper & Beneke, 2008).  
 
Our results show a very significant increase in Hb, HCT, and Ret% after treating our subjects with rHuEpo 
at a dose of 70 IU/kg for a two-week period.  This was accompanied by a significant decrease in the OFF-
Hr Score after the treatment. Administration of 4.3 µg/kg of desmopressin + 1.5 liters of water was 
sufficient to restore the Hb and HCT values to almost the basal levels. Regarding reticulocytes, the 
administration of desmopressin+ water decreased its value (slightly from 1.5 ± 0.4, after rHuEpo treatment, 
to 1.3 ± 0.5 after desmopressin treatment) although the basal levels were not achieved (0.7 ± 0.1). Finally 
the OFF-Hr Score decreased significantly after treatment with desmopressin in combination with water. It 
has been reported that intravenous infusion of Gelofusine (a PVE), in recreationally active men, results in a 
significant reduction in Hb concentration (g/dL) (16.0 preinfusion vs. 14.7 postinfusion; p < 0.001) and in the 
HCT (%) (44.0 preinfusion vs. 41.0  postinfusion; p < 0.01) (Berger et al., 2006). Taking these values into 
account we consider that our results confirm that treatment with desmopressin is similar to the 
administration of a PVE (Sanchis-Gomar et al., 2010b). 
 
In a recent paper we demonstrated the hemodilution effect of demospressin in a group of healthy subjects 
not being treated with erythropoiesis stimulating agents (Sanchis-Gomar et al., 2010b). The novelty of the 
present study lies in the demonstration that desmospressin has a very effective and fast hemodilution effect 
in a group of subjects treated with rHuEpo. Consequently, we consider that these results reinforce the main 
conclusion reported in our first study (Sanchis-Gomar et al., 2010b) and confirm that desmopressin is a 
masking agent for blood doping in sports.  
 
In our study published in 2010, we concluded that the hemodilution effect of the treatment 
(desmopressin+1.5 liters of water) was due to the properties of the drug and not to the water. We 
administered 1.5 liters of mineral water to the subjects and no modifications in the hematological 
parameters tested were found (Sanchis-Gomar et al., 2010b). Therefore, our main conclusion is that 
treatment with 4.3 µg/kg of desmopressin and 1.5 liters of water, after rHuEpo administration, significantly 
decreases the hematological values measured by the anti-doping authorities to detect blood doping. This 
fact is extremely important. In 2009, the UCI’s Biological Passport programme collected 6,165 blood 
samples but only 2,165 accompanying urine samples were tested for rHuEpo (Zorzoli & Rossi, 2010). Only 
if an athlete has an irregular blood value. The anti-doping authorities perform anti-EPO urine analyses 
(Lasne, 2001). Thus finding new hematological variables or methods resistant to plasma volume changes is 
crucial to detect blood doping (Sanchis-Gomar et al., 2010a). 
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